6CL3
LyeTxI-b, a synthetic peptide derived from Lycosa erythrognatha spider venom, shows potent antibiotic activity, in vitro and in vivo
Summary for 6CL3
| Entry DOI | 10.2210/pdb6cl3/pdb |
| NMR Information | BMRB: 30424 |
| Descriptor | Toxin LyeTx 1 (1 entity in total) |
| Functional Keywords | antimicrobial peptide, antimicrobial protein |
| Biological source | Lycosa erythrognatha (Spider) |
| Cellular location | Secreted : C0HJU9 |
| Total number of polymer chains | 1 |
| Total formula weight | 2725.41 |
| Authors | de Lima, M.E.,dos Reis, P.V.,Resende, J.M.,Verly, R.M. (deposition date: 2018-03-01, release date: 2018-05-30, Last modification date: 2024-10-23) |
| Primary citation | Reis, P.V.M.,Boff, D.,Verly, R.M.,Melo-Braga, M.N.,Cortes, M.E.,Santos, D.M.,Pimenta, A.M.C.,Amaral, F.A.,Resende, J.M.,de Lima, M.E. LyeTxI-b, a Synthetic Peptide Derived FromLycosa erythrognathaSpider Venom, Shows Potent Antibiotic Activityin Vitroandin Vivo. Front Microbiol, 9:667-667, 2018 Cited by PubMed Abstract: The antimicrobial peptide LyeTxI isolated from the venom of the spider is a potential model to develop new antibiotics against bacteria and fungi. In this work, we studied a peptide derived from LyeTxI, named LyeTxI-b, and characterized its structural profile and its and antimicrobial activities. Compared to LyeTxI, LyeTxI-b has an acetylated N-terminal and a deletion of a His residue, as structural modifications. The secondary structure of LyeTxI-b is a well-defined helical segment, from the second amino acid to the amidated C-terminal, with no clear partition between hydrophobic and hydrophilic faces. Moreover, LyeTxI-b shows a potent antimicrobial activity against Gram-positive and Gram-negative planktonic bacteria, being 10-fold more active than the native peptide against LyeTxI-b was also active in an model of septic arthritis, reducing the number of bacteria load, the migration of immune cells, the level of IL-1β cytokine and CXCL1 chemokine, as well as preventing cartilage damage. Our results show that LyeTxI-b is a potential therapeutic model for the development of new antibiotics against Gram-positive and Gram-negative bacteria. PubMed: 29681894DOI: 10.3389/fmicb.2018.00667 PDB entries with the same primary citation |
| Experimental method | SOLUTION NMR |
Structure validation
Download full validation report
